Pay in 4 interest-free payments of $5.67 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as semaglutide, improve glycemic control and are associated with weight loss, but the impact of weight loss on major adverse cardiovascular events (MACE) when taking semaglutide is not fully understood
The LEAD clinical trials, which began in 2006 and included thousands of participants worldwide, demonstrated liraglutides ability to improve glycemic control and promote weight loss (35)
The main European GLP-1 market is Germany, the United Kingdom, France, and Scandinavia, with good diabetes prescription practices following guidelines
K.ScholthofK
The demand for weight-loss medication also makes it a potential hotspot for criminal activity, with unregulated suppliers acting illegally and sometimes selling drugs that do not contain medication as labelled and put patients health at risk
(Source for lack of human PK data)
US$ 22.32
US$ 27.30
US$ 21.89
US$ 22.84
